

10264 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

It is interesting to note that Vicities' statement discloses a "Double Standard" philosophy adopted by the DoD - that is :

"The products of reputable, research-oriented companies
are not tested regularly***

Mr. Vicities statement apparently was composed by Mr. Max Feinberg - as Mr. Vicities could not have been privy to this information.

Too, in Vicities' address, delivered almost 3 years ago, he employed similar rhetoric as does Mr. Feinberg today.

i.e. "Inspectors from the department have uncovered substandard sanitary conditions and a general absence of even rudimentary quality control in a number of small, back-alley drug manufacturing plants, some of which have been set up by fast buck operators."

Examples of -

"Government compounds the propaganda of the large companies who for their own selfish interests espouse the superiority of their comparable products."

Bristol Laboratories, Ciba Pharmaceutical Company, Eaton Laboratories, Lederle Laboratories, Eli Lilly & Co. and Stuart Pharmaceuticals are so assured of their contract awards from the DoD that they have paid advertisements listing the respective Federal Stock Numbers for their products in the Physicians' Desk Reference." The listing had to be submitted 1/2 year (6 months) prior to publication.

i.e. PDR-1972 page 598

Bristol Labs.

"Polycillin" (Ampicillin trihydrate)

FSN 6505-770-8343

FSN 6505-935-1148

FSN 6505-181-7635

FSN 6505-926-8924

FSN 6505-827-5710

FSN 6505-935-6535

PDR-1974 page 697

Ciba Pharmaceutical Company

Serpasil tablets (Resperine)

FSN 6505-957-9531